{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-001140","form_type":"8-K","ticker":"VBIO","cik":"0001787740","company_name":"Valion Bio, Inc.","filed_at":"2025-01-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:04.867534+00:00","generated_at":"2026-05-28T15:01:22.182562+00:00","sec_items":["3.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Tivic Health receives Nasdaq delisting notice; hearing requested, reverse split proposed","bullets":["Nasdaq notified Tivic on Dec 27, 2024 it failed to regain $1.00 bid price compliance and is ineligible for a second 180-day period due to equity deficiency.","Company requested a hearing on Jan 3, 2025, which automatically stays any suspension or delisting pending the hearing and Panel decision.","Special stockholder meeting set for Jan 31, 2025 to vote on reverse stock split (ratio 1:2 to 1:30) to regain bid price compliance.","No assurance that the company will regain compliance or that the Nasdaq Panel will grant continued listing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-001140","json":"https://secwatch.observer/filing/0000950170-25-001140.json","markdown":"https://secwatch.observer/filing/0000950170-25-001140.md","text":"https://secwatch.observer/filing/0000950170-25-001140.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1787740/000095017025001140/0000950170-25-001140-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1787740/000095017025001140/tivc-20241227.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-28T15:01:22.182562+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"13eaed839bc9a42b778630d11f696fa7bdf241ba","claim":"Valion Bio, Inc. received a nasdaq delisting notice notice regarding stockholders equity.","evidence_excerpt":"December 27, 2024, the Company received an additional letter from Nasdaq, notifying the Company that it has not regained compliance with the Rule and is not eligible for a second 180-day remediation period. Specifically","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787740/000095017025001140/0000950170-25-001140-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Deficiency","value":"stockholders equity"}],"fact_type":"exchange_compliance_notice"},{"claim_id":"198e3e0c8d9c7f8524370ff7ad45036ab426291a","claim":"Valion Bio, Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).","evidence_excerpt":"December 27, 2024, the Company received an additional letter from Nasdaq, notifying the Company that it has not regained compliance with the Rule and is not eligible for a second 180-day remediation period. Specifically","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/1787740/000095017025001140/0000950170-25-001140-index.htm","confidence":0.9,"family_label":"Listing & Compliance Notices","details":[{"label":"Exchange","value":"nasdaq"},{"label":"Notice","value":"delisting notice"},{"label":"Deficiency","value":"minimum bid price"},{"label":"Rules","value":"5550(a)(2)"}],"fact_type":"exchange_compliance_notice"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}